Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.48
+0.25 (2.71%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Atara Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $13.67. The average 1-year stock price forecast is 44.20% higher than the current stock price, while the lowest is $10 (+5.49%) and the highest is $18 (+89.87%).
Price Target: $13.67 (+44.20%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Atara Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | May '26 | Jun '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $13 | Buy | Maintains | $13 | +37.13% | Oct 1, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $18 | Buy | Maintains | $18 | +89.87% | Aug 31, 2026 |
| Freedom Capital Markets | Freedom Capital Markets | Hold Upgrades $4 → $10 | Hold | Upgrades | $4 → $10 | +5.49% | May 18, 2026 |
Financial Forecast
Revenue This Year
2.85M
from 120.77M
Decreased by -97.64%
Revenue Next Year
40.87M
from 2.85M
Increased by 1,334.59%
EPS This Year
-0.95
from 2.57
EPS Next Year
1.55
from -0.95
EPS and Forward PE are based on non-GAAP adjusted numbers.